ATLANTA--(BUSINESS WIRE)--Inhibitex, Inc. (Nasdaq: INHX), a biopharmaceutical company focused on developing products to treat and prevent serious infectious diseases, today announced that its Investigational New Drug application (IND) for FV-100, its oral nucleoside analogue in development for the treatment of herpes zoster (shingles), has been accepted by the U.S. Food and Drug Administration (FDA). The Company has enrolled the first cohort (100 mg) in a Phase I clinical trial that will evaluate the safety and pharmacokinetics of up to four single ascending doses of FV-100 in healthy subjects. Each dose cohort will include six subjects who will receive FV-100 and two subjects who will receive placebo.